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INTRODUCTION
Since Lynch first described two major cancer families in 1966 
[1], Lynch syndrome or hereditary nonpolyposis colorectal 
cancer (HNPCC) has been reported to occur in a variety of 
extracolonic sites. He described gynecologic malignancies in-
cluding 15 uterine, four ovarian, and one cervical cancer in his 
original publication of major cancer families. Autosomal germ-
line mutations of DNA mismatch repair genes are thought to 
give rise to Lynch syndrome. The most commonly affected 
genes are MLH1 (40-45% of cases), MSH2 (40-45%), MSH6 (5-
10%), and PMS2 (<5%) [2-7]. These genetic defects in the DNA 
mismatch repair system result in replication errors in repetitive 
DNA segments, known as microsatellite instability (MSI), and 
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Objective: Lynch syndrome is a hereditary cancer syndrome that increases the risks of colorectal and gynecologic malignancies 
such as endometrial and ovarian cancer. Studies have shown that mutations in mismatch repair genes (MSH2, MSH6, and 
MLH1) are associated with Lynch syndrome. The aim of our study was to estimate the value of MSH2, MSH6, and MLH1 
immunohistochemistry based on family history in a Korean sample.
Methods: Thirty six women with synchronous gynecologic tumors of endometrial and ovarian cancer were identified among 
patients being treated at our institution. Among them, 32 patients had tumor blocks (total 62 slides) available for analysis. 
According to a diagnostic algorithm, we performed immunohistochemistry analyses. Staining was scored based on intensity 
and proportion (negative or 0: intensity undetectable or minimal, proportion <5%; weak or 1+: intensity mild, proportion 5-30%; 
strong or 2+: intensity moderate to marked, proportion 30-99%).
Results: Among 32 eligible patients, 9 (28%) had a family history of cancer. Six patients (19%) were negative for MLH1; among 
them, four (4/6) were negative at both sites. Nine patients (28%) were negative for MSH2 or MSH6 at both sites or negative 
for both MSH2 and MSH6. Among these three patients showed negative staining for both sites. The three patients showing 
negative staining for MLH1, MSH2, and MSH6 at both sites with family history were considered to be the screening positive 
groups of Lynch syndrome.
Conclusion: In this study, the frequency of Lynch syndrome associated immunohistochemical staining (MLH1, MSH2, and MSH6) 
group was estimated as 9% (3/32) among Korean women with synchronous gynecologic tumors.
Keywords: Lynch syndrome, Synchronous gynecologic tumor
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the absence of protein expression in the tumor. Currently, the 
diagnosis of Lynch syndrome is diagnosed based on family 
history, immunohistochemistry (IHC), MSI, and gene sequenc-
ing chromatogram (revised Amsterdam, 1998 [8] or Bethesda, 
2002 [9] criteria). 
Endometrial and ovarian cancers have been reported to oc-
cur in 60% and 12% of patients with Lynch syndrome, respec-
tively [10,11]. Synchronous (or multiple primary) gynecologic 
tumors are uncommon. Among such cases, a previous study 
estimated the frequency of Lynch syndrome to be 7-14% ac-
cording to clinical and molecular diagnostic algorithms [12, 
13].
Frequency of Lynch syndrome in Korean endometrial cancer 
patients has been reported to be 3.5% (4/113) [14] and 11.2% 
(18/161) [15], but there are no reports describing synchronous 
gynecologic tumors. Therefore, we undertook the present 
study to evaluate the frequency of Lynch syndrome in Korean 
women with synchronous gynecologic tumors including endo-
metrial and ovarian cancers based on family history and IHC.
MATERIALS AND METHODS 
Our study sample was identified through a search of medi-
cal records. Between 1995 and 2010, we identified 36 women 
with synchronous cancers (endometrial and ovarian, n=36) 
patients who underwent treatment at Samsung Medical 
Center. Clinical and pathologic data were obtained. Inclusion 
criteria were: 1) synchronous gynecologic malignancy (combi-
nation of two types among endometrial and ovarian cancer); 
and 2) family history of cancer confirmed by medical records 
and telephone interview. Patients were categorized into risk 
Fig. 1. Immunohistochemical analysis of MLH1, MSH2, and MSH6.Synchronous gynecologic malignancy and Lynch syndrome
J Gynecol Oncol Vol. 22, No. 4:233-238 www.ejgo.org 235
groups based on reported family history: high risk (family his-
tory of cancer), and low risk (no relevant family history). Family 
history was evaluated by medical records about site of cancer, 
age of diagnosis and relation from patient. But when medical 
records were incomplete, telephone interviews were done.
National Cancer Institute’s Surveillance, Epidemiology, and 
End Results (SEER) defines synchronous tumor as diagnosed 
two sites tumors within 2 months of each other. Our institu-
tion followed the criteria [16]. A gynecologic pathologist (SYS) 
reviewed the hematoxylin and eosin-stained slides from all tu-
mors to confirm the diagnosis of synchronous primary cancers 
based on characteristic findings (no tumor between two sites, 
no metastasis or spread of disease from one site to another).
All independent gynecologic synchronous primary tumors 
confirmed based on the criteria by Scully et al. [17] in 1998 
were included. Metastasis and spread from other sites were 
excluded. Sixty two paraffin-embedded tumor blocks were 
available for 32 patients. 
IHC analysis was performed on all tumor specimens to de-
termine the protein expression of MSH2, MSH6, and MLH1. As 
shown in Fig. 1, staining was scored based on intensity and 
proportion (negative or 0: intensity undetectable or minimal, 
proportion <5%; weak or 1+: intensity mild, proportion 5-30%; 
strong or 2+: intensity moderate to marked, proportion 30-99%).
For IHC analysis, monoclonal antibodies against MSH2 (Leica 
microsystems, Wetzlar, Germany), MSH6 (BD Transduction La  bo-
ratories, Lexington, KY, USA), and MLH1 (Leica microsystems) 
were used. Immunostaining was performed with Bond-Max (Leica 
microsystems) according to the manufacturer’s instructions. The 
normal staining patterns for MSH2, MSH6, and MLH1 are nu-
clear. Loss of expression of MSH2, MSH6, and MLH1 in cancer 
cells was demonstrated by the total absence of nuclear stain-
ing in the tumor. Adjacent normal stroma or infiltrating lym-
phocytes served as an internal positive control for each case. 
Nuclear staining of the tumor was scored as either 2 (strong), 
1 (weak), or 0 (negative) compared with the corresponding 
internal control. 
Once all data were collected, the likelihood of each patient 
having Lynch syndrome/HNPCC was determined based on a 
combination of clinical and IHC criteria that included a fam-
ily history consistent with Lynch syndrome and MLH1, MSH2, 
and MSH6 protein expression (both tumor sites negative or 
negative staining for more than two of these proteins). 
RESULTS 
Demographic characteristics for the 36 patients are listed 
in Table 1. The median age at diagnosis was 48 years (range, 
26 to 71 years). Based on family history, 9 patients (25%) were 
considered high risk, and 27 (75%) were considered low risk. 
Fifty percent (18/36) were both endometrioid in histology 
(Table 2). The remaining were serous, mucinous, and mixed 
endometrioid and mucinous adenocarcinoma. The two most 
common ovarian histologies were endometrioid (n=18), and 
mucinous (n=8), followed by serous (n=5), transitional (n=2), 
clear cell (n=2), and undifferentiated (n=2). Among the 32 
cases whose tumors were available, 15 patients (47%) had loss 
of at least one of the following: MSH2, MSH6, or MLH1 (Tables 
3 and 4). 
Six patients showed loss of MLH1 and the concordance rate 
of both tumor sites was 67% (4/6). Two patients showed weak 
MLH1 staining. Four patients showed results with both sites 
negative for MLH1 (4/6; cases 1-4 in Table 4). Among them 
case 2 is a high risk group.
Table 1. Demographic characteristics (n=36)
Characteristics Values
Median age (yr) 48 (26-71)
Premenopausal 30 (83)
Nulliparous 15 (42)
Family history of cancer  9 (25)
Median follow-up (mo) 39 (1-116)
Median PFS (mo) 35 (1-116)
Values are presented as value (range) or number (%).
PFS, progression free survival.
Table 2. Tumor types of patients
Pathology Total (n=36)
Both endometrioid 18
Endometrioid (E) + mucinous (O)   8
Others  10
E, endometrial; O, ovarian.
Table 3. Results of immunohistochemical analysis
Total at any site 
(32)
Concordance between 
tumor sites
Negative MLH1 6 (19) 4/6 (67)
High methylation rate
Negative MSH2 5 (16) 0/5
Negative MSH6 8 (25) 3/8 (38)
Negative for MSH2
  and/or MSH6
9 (28)
Normal  16 (50)
Values are presented as number (%).Min Kyu Kim, et al.
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Five patients were negative for MSH2 and 8 were negative 
for MSH6 at any site. Three patients showed weak staining 
for MSH2 and 5 showed weak staining for MSH6. Of the three 
with weak MSH2 staining, two showed weak MSH6 staining 
and one was negative for MSH6. Because of the high positive 
relationship between MSH2 and MSH6 staining and Lynch 
syndrome, we estimated that cases with both sites negative 
for MSH2 and MSH6 or negative for both proteins at any site 
were associated with Lynch syndrome (4/9 cases 5, 7, 8, 9 in 
Table 4). Among them cases 7 and 8 are high risk group. Case 
2, 7, and 8 had a family history and valid IHC results associated 
with Lynch syndrome risk.
In addition, we reserved 9 patients with low family history 
risk but appropriate staining results (negative MLH1, n=3 or 
negative MSH2 and MSH6, n=6) for further workup and ge-
netic tests. 
The frequency of Lynch syndrome was estimated as 9% 
(3/32) among Korean women with synchronous gynecologic 
tumors based on a combination of family history and IHC re-
sults (loss of MSH2, MSH6, and MLH1 expression). 
Fig. 2 provides a summary of our findings. The majority of 
patients (27/36, 75%) did not have family histories of cancer. 
Among these low-risk women, we were able to obtain 45 
tumor specimens. A few of these women had IHC findings 
suspicious of a MMR defect: three patients showed negative 
staining of MLH1 in both sites, one patient was MSH2 and 
MSH6 negative, and another was evaluated as MSH6 negative 
at both sites. 
Table 4. Characteristics of notable patients
Case
Age 
(yr)
Tumor 
site MLH1* MSH2* MSH6*
Family  history 
of cancer
1 57 E
O
0
0
2
2
2
2
2 53 E
O
0
0
2
2
2
2
Father: lung
 (unknown origin)
3 53 E
O
0
0
1
2
1
1
4 39 E
O 
0
0
2
2
1
2
5 26 E 
O 
1
2
0
2
0
2
6 39 E 
O 
2
2
0
1
2
1
Mother: colon
7 46 E 
O 
2
2
2
0
0
0
Mother: pancreas
Uncle: stomach
8 41 E 
O 
2
2
0
2
0
0
Father, sister:
 colon
9 51 E 
O 
2
2
0
2
0
0
10 46 E 
O 
2
2
2
2
0
2
11 55 E 
O 
2
2
2
2
0
1
12 38 E 
O 
2
2
2
2
0
2
13 44 E 
O 
2
0
2
2
2
2
Mother: stomach
14 53 E 
O 
1
2
1
2
0
1
15 53 E 
O 
NA
0
NA
2
NA
2
Uterine
E, endometrium; O, ovary; NA, not available.
*Values represent the score of immunohistochemical staining.
Fig. 2. Summary of results. IHC, immunohistochemistry; MSI, microsatellite instability.Synchronous gynecologic malignancy and Lynch syndrome
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DISCUSSION 
Among Lynch related cancers, endometrial cancer is much 
riskier than colorectal cancer in terms of lifetime incidence 
[18]. Ovarian cancer related to Lynch syndrome was reported 
to account for 3-14% of ovarian cancer patients. Considering 
gynecologic malignancy surgery principles, hysterectomy and 
oophorectomy can be performed in cases of either endome-
trial or ovary cancer. The uterus or the ovary can be saved for 
early stage and young women. Especially, ovary can be saved 
in early stage endometrial cancer. Therefore, Lynch syndrome-
related gynecologic malignancy takes a major part of it. 
Synchronous primary cancers of the endometrium and ovary 
have been identified in 7-29% of young women diagnosed 
with endometrial cancer [19,20]. Although the etiology of 
these cancers has not been clearly determined, familial cancer 
syndromes often account for patients diagnosed with multi-
ple cancers or patients diagnosed with cancer at a young age. 
Lynch syndrome (HNPCC) is an autosomal-dominant cancer 
predisposition syndrome that increases risk for multiple can-
cers.
Our study is the first report of the frequency of Lynch syn-
drome in synchronous gynecologic malignancy patients in 
Korea based on clinical and IHC criteria (MLH1, MSH2, and 
MSH6 protein expression). Our diagnosis was based on several 
clinical and IHC criteria. The IHC criteria were both sites nega-
tive for MLH1 or MSH2/MSH6, or negativity for both MSH2/6 
and MLH1 at any site. According to our algorithm, the fre-
quency of Lynch syndrome was estimated as 9% (3/36) (case 
2, 7, 8 in Table 4) among Korean women with synchronous 
gynecologic tumors.
The frequency of Lynch syndrome in synchronous gyneco-
logic tumors (combination of endometrium and ovary) has 
been reported to be 7% (7/102) [12] and 14% (3/22) [13]: how-
ever, more expensive and more precise gene tests were used 
(e.g., MSI or gene sequencing) and Asians represented only 
2-14% of the study samples (2/102 and 3/22). Therefore, our 
study provides pilot results suggestive of a prospective study. 
Based on our findings, we can better counsel patients at risk 
of this syndrome and their relatives regarding an expensive 
gene test for prevention of other cancers. 
Our recommendations for future study are: 1) multicenter 
investigation of synchronous gynecologic malignancy; 2) cost 
effective and appropriate selection of genetic testing for pa-
tients; 3) efficient MLH1, MSH2, and MSH6 IHC analysis during 
endometrial or cervical biopsy for patients with family history 
of cancer; 4) cooperation and close follow-up with a gastroin-
testinal physician. 
Limitations of our study are: 1) some family histories are 
missing. When medical records did not specify onset of cancer 
age and relationship from patient, telephone interviews were 
done. But because of memory loss and reluctance to reveal 
family secrets, they were not complete; 2) IHC is just screening 
test. Additional MSI, methylation and gene sequencing tests 
will confirm germline mutations. Although we must consider 
the high methylation rate of MLH1 and the sensitivity of stain-
ing, we propose a high probability of Lynch syndrome in 
patients with both sites negative for MLH1 (4/8; cases 1-4 in 
Table 4).
In summary, 9% (3/32) of women with synchronous gyne-
cologic tumors had either clinical or IHC criteria suggestive of 
Lynch syndrome. Therefore, we conclude that identifying sus-
picious Lynch syndrome patients though acquisition of family 
history and IHC can prepare us for better consultation and ef-
ficient prevention of multiple cancers. 
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